论文部分内容阅读
目的比较不同剂量氨溴索治疗社区相关肺炎的效果,并对其安全性进行评估。方法选取2014年1月至2015年6月收治的120例社区相关性肺炎患者作为研究对象,随机分为试验组和对照组。对照组予以氨溴索30 mg,3次/d,静脉滴注;试验组予以氨溴索30 mg,2次/d,静脉滴注,共治疗7 d。治疗后,观察并比较两组患者的临床症状评分、不良反应发生情况及临床疗效。结果治疗后两组临床症状评分均较治疗前明显下降,但试验组下降幅度较对照组更大,差异均有统计学意义(P<0.05)。试验组总不良反应发生率为15.0%,对照组为33.3%,两组比较差异有统计学意义(P<0.05)。试验组总有效率为86.7%,对照组为66.7%,差异有统计学意义(P<0.05)。结论增加氨溴索剂量可有效改善社区获得性肺炎的临床症状,降低其不良反应发生率,提高治愈率,值得临床进一步深入研究。
Objective To compare the efficacy of different doses of ambroxol in the treatment of community-related pneumonia and evaluate their safety. Methods A total of 120 patients with community-associated pneumonia admitted from January 2014 to June 2015 were selected as study subjects and randomly divided into experimental group and control group. The control group was ambroxol 30 mg, 3 times / d, intravenous infusion; the experimental group was given ambroxol 30 mg, 2 times / d, intravenous infusion, a total of 7 days. After treatment, clinical symptom scores, adverse reactions and clinical efficacy were observed and compared between the two groups. Results After treatment, the scores of clinical symptoms in both groups were significantly lower than those before treatment, but the decreasing rate in the experimental group was larger than that in the control group (P <0.05). The incidence of adverse reactions was 15.0% in the experimental group and 33.3% in the control group, with significant difference between the two groups (P <0.05). The total effective rate was 86.7% in the experimental group and 66.7% in the control group, the difference was statistically significant (P <0.05). Conclusion Increasing dose of ambroxol can effectively improve the clinical symptoms of community-acquired pneumonia, reduce the incidence of adverse reactions and improve the cure rate, it is worth further study in clinical.